VYNE THERAPEUTICS INC

🇮🇱Israel

Country: 🇮🇱Israel

Ownership: -

Employees: -

Market Cap: $26.5M

Website

Clinical Trials

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

Phase 2

Recruiting

Conditions: Non-segmental Vitiligo

Interventions: Drug: VYN201 Gel
Drug: Vehicle Gel

First Posted Date: 2024-07-10

Last Posted Date: 2024-08-09

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 160

Registration Number: NCT06493578

Locations: 🇺🇸
Saguaro Dermatology, Phoenix, Arizona, United States
🇺🇸
Clinical Trial Institute of Northwest Arkansas, LLC, Fayetteville, Arkansas, United States
🇺🇸
Palmtree Clinical Research, Inc., Palm Springs, California, United States

and more 44 locations

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: FMX114
Other: Vehicle

First Posted Date: 2021-06-16

Last Posted Date: 2022-08-31

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 21

Registration Number: NCT04927572

Locations: 🇺🇸
Investigator #14, Miami, Florida, United States
🇺🇸
Investigator #9, Miami, Florida, United States
🇦🇺
Investigational Site #1, Adelaide, South Australia, Australia

and more 4 locations

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Phase 3

Completed

Conditions: Facial Papulopustular Rosacea

Interventions: Drug: FMX103 minocycline foam 1.5%
Drug: Vehicle foam

First Posted Date: 2020-10-29

Last Posted Date: 2021-01-07

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 771

Registration Number: NCT04608500

Locations: 🇺🇸
Foamix Investigational Site #247, Hialeah, Florida, United States
🇺🇸
Foamix Investigational Site #252, Hialeah, Florida, United States
🇺🇸
Foamix Investigational Site # 228, Knoxville, Tennessee, United States

and more 43 locations

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

Phase 2

Completed

Conditions: Acne Vulgaris

Interventions: Combination Product: FCD105
Drug: 0.3% Adapalene Foam
Other: Vehicle Foam
Drug: 3% Minocycline Foam

First Posted Date: 2019-09-26

Last Posted Date: 2021-02-05

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 446

Registration Number: NCT04104685

Locations: 🇺🇸
Foamix Institution #126, Baton Rouge, Louisiana, United States
🇺🇸
Foamix Institution #107, Hialeah, Florida, United States
🇺🇸
Foamix Institution #132, San Diego, California, United States

and more 32 locations

Dermal Photo Allergic Skin Reaction

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: FMX-101

First Posted Date: 2019-08-28

Last Posted Date: 2019-08-28

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 56

Registration Number: NCT04070755

Dermal Phototoxicity Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: FMX101

First Posted Date: 2019-08-28

Last Posted Date: 2019-09-11

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 32

Registration Number: NCT04070742

Dermal Cumulative Irritant Patch Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: FMX-101

First Posted Date: 2019-08-21

Last Posted Date: 2019-08-28

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 42

Registration Number: NCT04064125

A Randomized, Controlled Study to Evaluate the Sensitizing Potential of FMX-101 in Healthy Volunteers Using a Repeat Insult Patch Test Design

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: FMX-101

First Posted Date: 2019-08-12

Last Posted Date: 2019-08-21

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 233

Registration Number: NCT04052711

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

Phase 2

Completed

Conditions: Pruritus

Interventions: Drug: Matching Placebo Tablets
Drug: 5 mg Serlopitant Tablets

First Posted Date: 2019-02-15

Last Posted Date: 2021-05-20

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 233

Registration Number: NCT03841331

Locations: 🇺🇸
Study Site 807, Miami, Florida, United States
🇺🇸
Study Site 121, Ocean Township, New Jersey, United States
🇺🇸
Study Site 813, Las Vegas, Nevada, United States

and more 38 locations

A Study Comparing Two Topicals in the Treatment of Acne Vulgaris

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: FMX101 vehicle
Other: Hydro-alcohol solution

First Posted Date: 2018-11-15

Last Posted Date: 2021-04-06

Lead Sponsor: Vyne Therapeutics Inc.

Target Recruit Count: 12

Registration Number: NCT03743038

Locations: 🇺🇸
Site #01, San Diego, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy